Relationship Between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jan 4

PMID 28046068

Citations 11

Authors

Tatsunori Toida

Takashi Iwakiri

Yuji Sato

Hiroyuki Komatsu

Kazuo Kitamura

Shouichi Fujimoto

Affiliations

Soon will be listed here.

Abstract

Background: Although hemoglobin (Hb) levels are affected by a change in the body fluid status, the relationship between Hb levels and mortality while taking interdialytic weight gain (IDWG) at blood sampling into account has not yet been examined in hemodialysis patients.

Study Design: Cohort study.

Setting, Participants: Data from the Miyazaki Dialysis cohort study, including 1375 prevalent hemodialysis patients (median age (interquartile range), 69 (60-77) years, 42.3% female).

Predictor: Patients were divided into 5 categories according to baseline Hb levels and two groups based on the median value of IDWG rates at blood sampling at pre-HD on the first dialysis session of the week.

Outcomes: All-cause and cardiovascular mortalities during a 3-year follow-up.

Measurements: Hazard ratios were estimated using a Cox model for the relationship between Hb categories and mortality, and adjusted for potential confounders such as age, sex, dialysis duration, erythropoiesis-stimulating agent dosage, Kt/V, comorbid conditions, anti-hypertensive drug use, serum albumin, serum C-reactive protein, serum ferritin, and serum intact parathyroid hormone. Patients with Hb levels of 9-9.9 g/dL were set as our reference category.

Results: A total of 246 patients (18%) died of all-cause mortality, including 112 cardiovascular deaths. Lower Hb levels (<9.0g/dL) were associated with all-cause mortality (adjusted HRs 2.043 [95% CI, 1.347-3.009]), while Hb levels were not associated with cardiovascular mortality. When patients were divided into two groups using the median value of IDWG rates (high IDWG, ≥5.4% and low IDWG, <5.4%), the correlation between lower Hb levels and all-cause mortality disappeared in high IDWG patients, but was maintained in low IDWG patients (adjusted HRs 3.058 [95% CI,1.575-5.934]). On the other hand, higher Hb levels (≥12g/dL) were associated with cardiovascular mortality in high IDWG patients (adjusted HRs 2.724 [95% CI, 1.010-7.349]), but not in low IDWG patients.

Conclusion: In hemodialysis patients, target Hb levels may need to be selected in consideration of IDWG at blood sampling.

Citing Articles

Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.

Garbelli M, Baro Salvador M, Rincon Bello A, Samaniego Toro D, Bellocchio F, Fumagalli L Biomedicines. 2024; 12(10).

PMID: 39457532 PMC: 11504963. DOI: 10.3390/biomedicines12102219.

Risk factors for short-term all-cause mortality in patients with end stage renal disease: a scoping review.

Yip W, Ng S, Kaur P, George P, Guan J, Lee G BMC Nephrol. 2024; 25(1):71.

PMID: 38413903 PMC: 10900550. DOI: 10.1186/s12882-024-03503-3.

Predictive role of cardiac valvular calcification in all-cause mortality of Chinese initial haemodialysis patients: a follow-up study of 4 years.

Cheng Y, Lu Z, Cao X, Ding X, Zou J, Jin H BMC Nephrol. 2023; 24(1):37.

PMID: 36792978 PMC: 9933363. DOI: 10.1186/s12882-023-03076-7.

Executive summary of the Korean Society of Nephrology 2021 clinical practice guideline for optimal hemodialysis treatment.

Jung J, Yoo K, Kang E, Kang H, Kim S, Kim H Korean J Intern Med. 2022; 37(4):701-718.

PMID: 35811360 PMC: 9271711. DOI: 10.3904/kjim.2021.543.

Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.

Jung J, Yoo K, Kang E, Kang H, Kim S, Kim H Kidney Res Clin Pract. 2021; 40(Suppl 1):S1-S37.

PMID: 34923803 PMC: 8694695. DOI: 10.23876/j.krcp.21.600.

References

Agrawal V, Mukherjee S, Kosuri R, Dumler F . Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience. Am J Ther. 2009; 17(5):469-75. DOI: 10.1097/MJT.0b013e3181b28b59. View

Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M . Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010; 14(4):349-55. DOI: 10.1007/s10157-010-0288-x. View

Icardi A, Sacco P, Salvatore F, Romano U . Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients. J Nephrol. 2007; 20(1):73-9. View

Inaba M, Hayashino Y, Shoji T, Akiba T, Akizawa T, Saito A . Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study. Nephron Clin Pract. 2012; 120(2):c91-c100. DOI: 10.1159/000335979. View

Kwon O, Jang H, Jung H, Kim Y, Kang S, Yang C . The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One. 2015; 10(10):e0140241. PMC: 4599895. DOI: 10.1371/journal.pone.0140241. View

Kalantar-Zadeh K, Don B, Rodriguez R, HUMPHREYS M . Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001; 37(3):564-72. View

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T . Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86(4):845-54. DOI: 10.1038/ki.2014.114. View

Johansen K, Finkelstein F, Revicki D, Evans C, Wan S, Gitlin M . Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2011; 27(6):2418-25. DOI: 10.1093/ndt/gfr697. View

Akizawa T, Pisoni R, Akiba T, Saito A, Fukuhara S, Asano Y . Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant. 2008; 23(11):3643-53. PMC: 2568010. DOI: 10.1093/ndt/gfn346. View

10.

Foley R, Curtis B, Parfrey P . Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol. 2009; 4(4):726-33. PMC: 2666430. DOI: 10.2215/CJN.04950908. View

11.

Vlassopoulos D, Sonikian M, Dardioti V, Hadjiconstantinou V . Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?. Nephrol Dial Transplant. 1999; 14(5):1340-1. DOI: 10.1093/ndt/14.5.1340. View

12.

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

13.

Corwin H, Gettinger A, Fabian T, May A, Pearl R, Heard S . Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007; 357(10):965-76. DOI: 10.1056/NEJMoa071533. View

14.

Palmer S, Navaneethan S, Craig J, Johnson D, Tonelli M, Garg A . Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153(1):23-33. DOI: 10.7326/0003-4819-153-1-201007060-00252. View

15.

Pascual J, Teruel J, Moya J, Liano F, Ortuno J . Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol. 1991; 35(6):280-7. View

16.

Johnson J, Gore S, Firth J . The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant. 1999; 14(9):2156-64. DOI: 10.1093/ndt/14.9.2156. View

17.

Akizawa T, Saito A, Gejyo F, Suzuki M, Nishizawa Y, Tomino Y . Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial. 2014; 18(5):404-13. DOI: 10.1111/1744-9987.12155. View

18.

Pisoni R, Bragg-Gresham J, Young E, Akizawa T, Asano Y, Locatelli F . Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44(1):94-111. DOI: 10.1053/j.ajkd.2004.03.023. View

19.

Locatelli F, Pisoni R, Combe C, Bommer J, Andreucci V, Piera L . Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2003; 19(1):121-32. DOI: 10.1093/ndt/gfg458. View

20.

van de Borne P, Tielemans C, Vanherweghem J, Degaute J . Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant. 1992; 7(1):45-9. View